Physician profile
Sabrina Lasseter
NPI 1083398739
$1,401.66
in general payments reported to CMS, 2019-2025
16 companies · $301 in 2025
The $301 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $479 · 2024: $622 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384 · Education: $17.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,384.32 |
| Education | $17.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $504.83 | 2023-2024 | Farxiga, Lokelma, Brilinta |
| Calliditas Therapeutics US INC. | $200.92 | 2023-2025 | Tarpeyo |
| Shield Therapeutics INC | $121.78 | 2024-2025 | |
| Amgen INC. | $120.48 | 2024-2025 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $97.41 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.94 | 2023-2025 | |
| Travere Therapeutics, INC. | $61.05 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $46.96 | 2023-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $28.73 | 2024 | Lupkynis |
| Novo Nordisk INC | $26.30 | 2025 | Ozempic |
| Vifor Pharma, INC. | $23.31 | 2024 | Veltassa |
| Ardelyx, INC. | $21.82 | 2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $17.87 | 2024 | Velphoro |
| Opko Pharmaceuticals, LLC | $17.34 | 2023 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.97 | 2025 | Jardiance |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $13.95 | 2024 | Jynarque |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabrina Lasseter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.